Company profile for NGM Biopharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients.Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-m...
We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients.Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
333 Oyster Point Blvd. South San Francisco, CA 94080
Telephone
Telephone
650-243-5555
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.fiercebiotech.com/biotech/ngm-bio-slims-down-strategic-pivot-cutting-75-staff-and-halting-mid-stage-liver-disease

FIERCE BIOTECH
13 May 2025

https://www.globenewswire.com/news-release/2025/02/24/3030878/35057/en/NGM-Bio-Announces-First-Participant-Dosed-in-EMERALD-Phase-2-Clinical-Study-of-NGM120-for-the-Treatment-of-Hyperemesis-Gravidarum-HG-in-Pregnant-Patients.html

GLOBENEWSWIRE
24 Feb 2025

https://www.globenewswire.com/news-release/2025/02/04/3020147/35057/en/NGM-Bio-Announces-Appointment-of-Wendy-Yeh-M-D-as-Chief-Medical-Officer.html

GLOBENEWSWIRE
04 Feb 2025

https://www.fiercebiotech.com/biotech/vc-firm-pens-608m-biobucks-deal-direct-ngms-mash-drug-rare-disease

FIERCE BIOTECH
20 Dec 2024

https://www.globenewswire.com/news-release/2024/12/19/2999734/35057/en/NGM-Bio-and-KdT-Ventures-Enter-into-Worldwide-License-Agreement-for-NGM313-a-Phase-2-ready-FGFR1c-%CE%B2-Klotho-Agonist-Drug-Candidate.html

GLOBENEWSWIRE
19 Dec 2024

https://www.fiercebiotech.com/biotech/3-months-after-taking-ngm-bio-private-vc-firm-oversees-biotechs-122m-series

FIERCE BIOTECH
17 Jul 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty